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Abstract
Background: Interferons play a critical role in regulating both the innate and adaptive immune
responses. Previous reports have shown increased levels of IFN-γ, IFN-γ-inducing IL-12 and IFN-γ-
inducible chemokine IP-10 in patients with chronic obstructive pulmonary disease (COPD).
Methods: The present study focuses on the regulation of the IP-10 secretion in co-cultures of lung
epithelial cells and peripheral blood mononuclear cells (PBMCs).
Results: No IP-10 secretion was detected in cells cultured alone, whereas a significant increase in
IP-10 levels was observed in epithelial cell/PBMC co-cultures. Furthermore, the results show that
interactions between lung epithelial cells, lymphocytes and monocytes are needed for basal IP-10
secretion. Interestingly, we have also shown that incubation with IL-12 can induce an IFN-γ
independent increase in IP-10 levels in co-cultures. Furthermore, inhibition studies supported the
suggestion that different intracellular pathways are responsible of IFN-γ and IL-12 mediated IP-10
secretion.
Conclusion: These studies demonstrate a novel diversity in IFN-γ/IL-12 pathways, showing that
the IP-10 expression in co-cultures is regulated by multiple factors, such as intercellular interactions
in addition to IFN-γ and IL-12 levels. These results may be valuable in designing novel strategies to
antagonize IP-10 mediated immunological reactions and chemotactic effects on T cells.
Background
Multiple inflammatory cells, mediators, and proteases are
involved in the pathophysiology of COPD. It is character-
ized by chronic inflammation primarily in the small air-
ways and lung parenchyma, with increased numbers of
macrophages, neutrophils and T lymphocytes in compar-
ison to healthy controls [1]. T helper (Th) lymphocytes
can be classified into two types depending on the secreted
cytokines. Th1 cells are mainly involved in cell-mediated
inflammatory reactions and in development of chronic
inflammatory conditions, whereas Th2 cells enhance anti-
body production by B cells and are prominent in the
pathogenesis of allergic diseases [2,3]. A bias towards a
Th1 cell profile has been hypothesized in COPD, with
Th1/T cytotoxic 1 (Tc1) pattern and increased Th1
cytokine levels [1].
Th1 cells secrete IL-2, IL-12, and IFN-γ, which has been
shown to regulate Th mediated immune and allergic
responses by inducing Th1 differentiation. IFN-γ secretion
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from natural killer (NK) cells and monocytes/macro-
phages is likely to be important in early host defence
against infection, whereas T lymphocytes become the
major source of IFN-γ in the adaptive immune response
[2,3].
IFN-γ-inducible protein 10 (IP-10) is induced by IFN-γ in
many types of cells including monocytes and lung epithe-
lial cells [4,5]. IP-10, also named CXCL10, is a potent
chemokine for activated T lymphocytes and regulates cell
proliferation, apoptosis and adhesion molecule expres-
sion [6]. Previous studies have shown that physical inter-
actions between cells grown in co-cultures induce IP-10
secretion; between endothelial cells (EnC)/monocytes
[7], EnC/alloantigen-primed T cells [8], EnC/PBMCs [9],
leucocytes/synoviocytes [10] as well as human bronchial
epithelial cell (BEAS-2B)/eosinophils [11]. The increased
IP-10 secretion in BEAS-2B/eosinophil co-cultures was
regulated by p38 MAPK and NF-kappaB activities of BEAS-
2B cells, at least partly via intercellular contact [11].
IP-10 binds to a G protein coupled receptor CXCR3 that is
preferentially expressed on Th1 type cells, causing chemo-
taxis of these cells towards this chemokine [12]. CXCR3 is
also expressed by many cell types including lung epithe-
lial cells [13,5,14] and it has been shown to be involved
in epithelial cell movement via p38 MAPK and PI3K
dependent signalling pathways in human airway epithe-
lial cells (HAEC) [15]. Furthermore, HAEC have also been
shown to release IP-10 as well as express CXCR3, suggest-
ing the potential for autocrine signalling [14].
IFN-γ-inducing cytokine IL-12 is produced by many cell
types including monocytes/macrophages, and neu-
trophils. The major actions of IL-12 are on T cells, result-
ing in induction of Th1 differentiation, proliferation, IFN-
γ production and increased cytotoxic activity. [16] Th1
cytokine phenotype has been demonstrated in peripheral
blood [17] and in lung portions removed surgically from
patients with COPD [18]. Furthermore, increased IL-12
levels have been shown in patients with COPD [19,20].
Relative expression levels of IFN-γ in COPD patients are
variable, with previous studies having shown an increase
[19,18], decrease [21] or no change [22] in IFN-γ secretion
in COPD patients compared with controls. Enhanced IP-
10 secretion [23,18,24] as well as expression of the IP-10
receptor CXCR3 [23] have been demonstrated in COPD.
As shown by Saetta et al. (2002), most of the CXCR3 pos-
itive cells in peripheral airways in patients with COPD
were CD8+ positive T cells and produced IFN-γ [23].
The present study focuses on the regulation of the IP-10
secretion. The aim was to investigate the pathways of IP-
10 secretion in a in vitro system including the cell types
most likely involved in the IP-10 secretion in the lung tis-
sue of COPD patients. Although several studies have dem-
onstrated an increased IP-10 secretion via intercellular
contact, little is known of the regulation of the Th1 IFN-γ/
IL-12 pathway upon intercellular interaction between
lung epithelial cells and leucocytes. Since increased activ-
ity of the IFN-γ/IL-12 pathway as well as increased levels
of IP-10 in COPD is most likely due to a complex interac-
tion between lung epithelial cells and white blood cells,
we decided to investigate the role of the IFN-γ/IL-12 path-
way on IP-10 secretion upon the interaction of peripheral
blood mononuclear cells with two human lung epithelial
cell lines, A549 (alveolar epithelial cell line), Calu-3
(bronchial epithelial cell line) in addition to primary nor-
mal human bronchial epithelial (NHBE) cells.
Materials and methods
Maintenance of human epithelial cell lines
Cells from a human bronchial epithelial cell line (Calu-3)
and from a human alveolar epithelial cell line (A549)
were used for the present studies. Both cell lines were cul-
tured routinely at 37°C with 5% CO2 in Minimum essen-
tial medium (MEM) with Earle's Salts and L-Glutamine
(Invitrogen) supplemented with 10% of heat-inactivated
foetal calf serum (FCS) (PAA Laboratories), 1.5% sodium
bicarbonate solution, (Sigma-Aldrich), 10 mM Sodium
pyruvate solution (Sigma-Aldrich), 1× MEM non-essential
amino acid solution (Sigma-Aldrich) and 1× Primocin
(Autogen Bioclear) in cell culture polystyrene flasks with
vent caps (Corning). The splitting of cell cultures was per-
formed by replacing the medium with cell dissociation
solution (Sigma-Aldrich). Both cell lines were used up to
32 passages.
Maintenance of normal human bronchial epithelial cells
Normal Human Bronchial Epithelial Cells (NHBEs) were
cultured according to the manufacturer's instructions
(Cambrex, Inc.). However, during the experiment and the
co-culture conditions, the NHBEs were transferred to the
Minimum essential medium (MEM) with Earle's Salts and
L-Glutamine (Invitrogen) supplemented with 1% foetal
calf serum (FCS) (PAA Laboratories).
Peripheral blood mononuclear cell (PBMC) Isolation
PBMCs were obtained from healthy non-smoking and
smoking adult volunteers. Usage of human blood for the
present studies was approved by the local ethical commit-
tee, and the informed consent of all participating subjects
was obtained. The venous blood was collected into 50 ml
centrifuge tubes each containing 5 ml of Hank's Balanced
Salt Solution (HBSS) (Sigma-Aldrich) with 2.7% (w/v)
Hepes (Sigma-Aldrich). The blood sample was diluted 1:1
with modified Dulbecco's phosphate buffered saline
(PBS) without calcium chloride and magnesium chloride
(Sigma-Aldrich). PBMCs were isolated with density cen-
trifugation with ACCUSPIN™ System-HISTOPAQUE-Respiratory Research 2007, 8:80 http://respiratory-research.com/content/8/1/80
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1077 tubes (Sigma-Aldrich) at 400 g for 35 minutes at
room temperature. Following centrifugation the layer
containing the PBMCs (according the manufacturer's
instructions) was collected, resuspended in PBS and cen-
trifuged at 200 g for 10 minutes at room temperature. The
supernatant was discarded and PBMC-rich pellet was
resuspended in cell media (See above in Maintenance of
Human Epithelial Cell Lines) with 1% FCS. A differential
cell count was performed using a Beckman-Coulter
Act5diff haematology analyzer to determine total cell
number and the purity of the cell preparation. This
method typically yields a cell suspension containing 80–
95% of lymphocytes and 5–20% monocytes. The cells
were resuspended in cell media with 1% FCS to 1 million
white blood cells/ml and plated in 48 well cell culture
polystyrene clusters (Corning) and cultured with or with-
out A549 or Calu-3 cells.
Conditioned media and transwell studies
PBMCs and lung epithelial cells were cultured alone in
cell media with 1% FCS for 18 hours. The cells were cen-
trifuged at 200 g for 5 minutes and the supernatant was
collected, filtered with sterile 0.22 um filters and frozen at
-80°C. For the experiments, PBMCs or lung epithelial cells
were resuspended in the conditioned media and cultured
for 18 hours.
For transwell studies, lung epithelial cells were grown to
80% confluency (approximately 1 × 105) on 12 well tran-
swell chambers (Corning). Subsequently lung epithelial
cells and 5 × 105 PBMCs are co-cultured (1,5 ml/well) for
18 hours in transwell chambers separated by a filter (0.4
µM pore size) or not (as control), where-after the superna-
tant was collected for IP-10 and IFN-γ ELISA analysis.
Isolation of lymphocytes from PBMCs
After resuspension in 1% FCS cell media to 1 × 106 white
blood cells/ml (see above in Peripheral Blood Mononuclear
Cell (PBMC) Isolation) the PBMCs were plated cell culture
polystyrene flasks for 1 hour in 37°C with 5% CO2. Since
monocytes attach to the plastic whereas lymphocytes stay
in suspension, the supernatant was collected after 1 hour
and centrifuged at 200 g for 5 minutes. A differential cell
count was performed using a Beckman-Coulter Act5diff
haematology analyzer to determine total cell number and
the purity of the cell preparation. This method typically
yields a cell suspension containing 99–100% of lym-
phocytes.
Isolatation of monocytes from PBMCs with MACS
PBMCs are incubated with anti-human CD14 antibody
conjugated to super-paramagnetic microbeads (Miltenyi
Biotec). Labelled suspensions are passed through a deple-
tion column in the magnetic field of a MACS separator
(Miltenyi Biotec) according to the manufacturer's instruc-
tions. A differential cell count was performed using a
Beckman-Coulter Act5diff haematology analyzer to deter-
mine total cell number and the purity of the cell prepara-
tion. This method typically yields a cell suspension
containing 70–100% of monocytes with a contamination
range between 0–30% of lymphocytes. Purity of 88%–
100% of monocytes was set as acceptable range for the
present studies with monocyte/lung epithelial cell co-cul-
ture studies.
Interferon and chemokine ELISA assays
Human IP-10 and IFN-γ levels were specifically quantified
with human IP-10 CytoSets™ and human IFN-γ CytoSets™
assays (Biosource). The epithelial cell lines were grown
into 80% confluency before the experiments whereas the
PBMCs were cultured at the density of 1 × 106 cells/ml.
The cultures were performed in 48 well clusters with 0.5
ml cell media (500 000 PBMCs/well) with or without
A549, Calu-3 and NHBEs. The epithelial cell lines and
PBMCs were cultured either alone or in co-culture in 48
well clusters for 18 hours in cell media (see above) with
1% FCS before the ELISA assay. Pretreatments were per-
formed with an addition of human recombinant IL-12
(100 ng/ml) (eBioscience) or human recombinant IFN-γ
(0.1–10 ng/ml) (eBioscience) for 18 hours. Potential
inhibitors 100 nM p38 inhibitor BIRB796, 500 nM IKK-2
inhibitor V, (Calbiochem), 100 nM beclomethasone (Sig-
maAldrich), 1 µM PI3 kinase inhibitor (Novartis, charac-
terised as PIK 93 in [25]), 100 nM PDE4 inhibitor
Rolipram (SigmaAldrich)), 5 µg/ml human IFN-γ anti-
body (Serotec MCA1554XZ) and 10 µg/ml human CD40
ab from (Serotec, MCA1590XZ), were added one hour
before addition of IL-12 or IFN-γ. The chosen concentra-
tion for the inhibitors were roughly 10× IC50 from
present and previous studies. All ELISA assays were per-
formed according to the manufacturer's instructions. Max-
isorp 96 well microplates (Nunc) were used for the assays
and Skanwasher 300 (Skatron Instrument) was used to
wash the microplates with 0.01 M PBS with 0.05% Tween
20 (pH 7.4) as the wash buffer. The results were read with
microplate reader (SpectraMax 250) at 450 nm.
Statistical analysis
All data are expressed as mean (ng/ml) ± SEM. All data
were transformed into logarithmic data before the statisti-
cal analysis and compared with analysis of variance
(ANOVA). The means of groups whose variances were
determined to be significantly different were then com-
pared by Bonferroni's multiple comparison test using
GraphPad Prism (GraphPad Software Inc., San Diego,
CA).Respiratory Research 2007, 8:80 http://respiratory-research.com/content/8/1/80
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Results
Basal and IFN-γ mediated IP-10 secretion from PBMC/lung 
epithelial cell co-cultures
IP-10 levels in cell culture medium collected after 18
hours from PBMCs, Calu-3, A549 and PBMC/lung epithe-
lial cell co-cultures were measured with ELISA. When
plated alone, very little secretion of IP-10 was detected
from unstimulated PBMCs and lung epithelial cell lines
(Figure 1. and 2.). However, significantly increased IP-10
secretion was detected in lung epithelial cell/PBMC co-
cultures (Figure 1.). The secretion from A549/PBMC co-
cultures was significantly higher than Calu-3/PBMC co-
cultures (p < 0.01, 0.88 ± 0.19 ng/ml and 0.22 ± 0.07 ng/
ml, respectively).
Pretreatment with recombinant IFN-γ for 18 h induced a
small dose-dependent increase in IP-10 secretion in
PBMCs cultured alone, whereas no detectable levels of IP-
10 were found in either Calu-3 or A549 cultured alone
(Figure 1). However, IFN-γ (0.1–10 ng/ml) induced a sig-
nificant dose dependent increase in IP-10 secretion in
lung epithelial cell – PBMC co-cultures as shown in Figure
1.
IL-12 induces endogenous IFN-γ secretion in PBMC/A549 
co-cultures
The presence of endogenous IFN-γ in supernatants col-
lected after 18 hours from PBMCs, lung epithelial cell
lines as well as in co-cultures was studied with ELISA. No
detectable levels of IFN-γ were shown in either un-stimu-
lated cells cultured alone or in co-cultures (Table 1). 18
hours incubation with recombinant IL-12 (100 ng/ml)
did not induce any detectable secretion of endogenous
IFN-γ in PBMCs, lung epithelial cell lines alone nor Calu-
3/PBMC co-cultures (Table 1.) However, a significant
increase in endogenous IFN-γ secretion was shown in
A549/PBMC co-cultures after IL-12 treatment (Table 1).
To establish the cell type in PBMCs interacting with the
A549 cell line, secretion of IFN-γ was studied in lym-
phocyte/A549 and monocyte/A549 co-cultures. As shown
in Table 1., lymphocytes exclusively interact with A549
resulting in a significant induction of IFN-γ secretion
upon IL-12 stimulation.
Table 1: Secretion of IFN-γ in lung epithelial cell lines and 
PBMCs.
+ IL-12
Cell media 0.002 ± 0.001
Calu-3 0.005 ± 0.003 0.002 ± 0
A549 0.006 ± 0.002 0.003 ± 0.002
PBMCs 0.007 ± 0.003 0.007 ± 0.003
Calu-3/PBMCs 0.004 ± 0.002 0.003 ± 0.001
A549/PBMCs 0.007 ± 0.003 1.624 ± 0.36***
A549/Lymphocytes 0.010 ± 0.04 1.889 ± 0.46***
A549/Monocytes 0.018 ± 0.01 0.027 ± 0.004
Supernatants were collected after 18 hours with or without IL-12 
(100 ng/ml) incubation (Data represent the mean (ng/ml) ± SEM of n 
= 4–10 independent experiments). Results expressed as means (ng/
ml) ± SEM, n = 4–10, ***p < 0.001 compared with co-cultures 
without IL-12 treatment, ANOVA with Bonferroni's multiple 
comparison test.
Basal and IFN-γ mediated secretion of IP-10 in lung epithelial  cell/PBMC co-cultures Figure 1
Basal and IFN-γ mediated secretion of IP-10 in lung epithelial 
cell/PBMC co-cultures. Data represent the mean ± SEM of 4 
independent experiments, ***p < 0.001, **p < 0.01, *p < 0.05 
compared to without IFN-γ treatment; ¤¤¤p < 0.001, ¤¤p < 
0.01, ¤p < 0.05 for each concentration of recombinant IFN-γ 
treatment in co-cultures compared to both PBMCS and 
respective lung epithelial cell lines cultured alone, ANOVA 
with Bonferroni's multiple comparison test.
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IL-12 (100 ng/ml) mediated secretion of IP-10 in lung epithe- lial cell/PBMC co-cultures Figure 2
IL-12 (100 ng/ml) mediated secretion of IP-10 in lung epithe-
lial cell/PBMC co-cultures. Data represent the mean ± SEM 
of 7–14 independent experiments, **p < 0.01, ANOVA with 
Bonferroni's multiple comparison test.
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IL-12 induces IP-10 secretion in PBMC/lung epithelial cell 
co-cultures
18 hours preincubation with IL-12 did not modulate IP-
10 secretion from cells cultured alone (Figure 2.). How-
ever, a significant increase in IP-10 secretion was observed
in both Calu-3/PBMC and A549/PBMC co-cultures upon
IL-12 pretreatment, as seen in Figure 2.
IL-12 and IFN-γ co-treatment in co-cultures
The effects of IL-12 (100 ng/ml) and IFN-γ (1 or 10 ng/ml)
co-treatment on IP-10 secretion was studied in Calu-3/
PBMC and A549/PBMC co-cultures. No additional
increase in IP-10 secretion was observed with IL-12 and
IFN-γ co-treatment in A549/PBMC co-cultures compared
with IL-12 or IFN-γ treatment alone (IP-10 secretion 3.7 ±
0.5 ng/ml (IL-12 100 ng/ml), 3.5 ± 7 ng/ml (IFN-γ 1 ng/
ml and 3.9 ± 0.7 ng/ml (IL-12 100 ng/ml+ IFN-γ 1 ng/
ml)). However, in Calu-3/PBMC co-cultures, the secretion
of IP-10 induced by IL-12 pretreatment was significantly
lower compared with IFN-γ induced IP-10 secretion (IP-
10 secretion 1.3 ± 0.2 ng/ml (IL-12 100 ng/ml), 2.6 ± 0.4
ng/ml (IFN-γ 1 ng/ml and 3.0 ± 0.7 ng/ml (IL-12 100 ng/
ml+ IFN-γ 1 ng/ml), which might be explained by the
absence of IL-12 mediated induction of endogenous IFN-
γ secretion when compared with A549/PBMC co-cultures
(See also Table 1).
Effects of IFN-γ antibody on IP-10 secretion
Treatment with 5 µg/ml IFN-γ antibody (ab) significantly
inhibited the basal IP-10 secretion in both Calu-3/PBMC
and A549/PBMC co-cultures (Figure 3.). The significant
increase of IP-10 secretion in co-cultures mediated via
recombinant (1–10 ng/ml) IFN-γ treatment was also
inhibited by the IFN-γ ab treatment. However, the IL-12
induced increase in IP-10 levels was not inhibited by the
IFN-γ ab, showing that at least a component of IL-12
mediated IP-10 increase is IFN-γ independent (Figure 3.).
Conditioned media and transwell studies
Studies with conditioned media (CM) showed that lung
epithelial cells are secreting a factor which augments IFN-
γ mediated IP-10 secretion from PBMCs. PBMCs cultured
with 10 ng/ml IFN-γ in CM from either Calu-3 or A549
cells induced a significant increase in IP-10 secretion com-
pared with PBMCs cultured with IFN-γ (Figure 4.) The IP-
10 is secreted by monocytes, since lymphocytes cultured
with CM media from epithelial cells did not induce any
IP-10 secretion (data not shown).
Furthermore, a secreted factor from Calu-3 cells augments
IL-12 mediated IP-10 secretion from PBMCs. PBMCs cul-
tured with 100 ng/ml IL-12 in CM from Calu-3 but not
from A549 cells induced significant increase in IP-10
secretion compared with PBMCs cultured with IL-12 (Fig-
ure 4). IP-10 is secreted by monocytes, since lymphocytes
cultured with CM media from Calu-3 did not induce any
IP-10 secretion (data not shown).
No detectable levels of IP-10 were secreted by lung epithe-
lial cells cultured in CM from PBMCs with or without IL-
12 or IFN-γ treatment (Figure 4). Moreover, IL-12 treat-
ment did not induce any detectable IFN-γ secretion from
either PBMCs or A549 cells cultured in CM from A549
cells or PBMCs, respectively (data not shown).
Transwell studies confirmed the results from conditioned
media studies, as can be seen in Figure 5. The co-cultures
were grown in transwell chambers separated (or not as
control) by a filter. There is an increased IP-10 secretion in
the presence of IFN-γ in co-cultures and a slight increase
after IL-12 treatment (See Figure 5.). However, the basal,
IFN-γ and IL-12 induced secretion of IP-10 in co-cultures
The effects of conditioned media (CM) on IP-10 secretion  from cells cultured alone Figure 4
The effects of conditioned media (CM) on IP-10 secretion 
from cells cultured alone. The lung epithelial cells or PBMCs 
were cultured for 18 hours in CM simultaneously with either 
IFN-γ (10 ng/ml) or IL-12 (100 ng/ml) incubation. PBMCs cul-
tured alone were used as control. Data represent the mean 
± SEM of 4–6 independent experiments, *p < 0.05, **p < 
0.01, ANOVA with Bonferroni's multiple comparison test.
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Inhibition of IP-10 secretion in lung epithelial cell/PBMC co- cultures by human IFN-γ antibody Figure 3
Inhibition of IP-10 secretion in lung epithelial cell/PBMC co-
cultures by human IFN-γ antibody.
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is significantly decreased when separated with filter as
compared to controls (Figure 5). These results confirm the
results from conditioned media studies but also show that
cell-cell interactions are likely to play an important role in
IP-10 secretion in PBMCs/lung epithelial cell co-cultures.
However, endogenous IFN-γ secretion in lymphocyte/
A549 co-cultures after IL-12 treatment was high (0.90 ±
0.45, mean (ng/ml) ± SEM, n = 3) even with separating fil-
ter, showing that although a co-culture of lymphocytes
and A549 cells is necessary for the secretion of IFN-γ, no
actual cell-cell contact is required.
Studies with monocyte or lymphocyte/lung epithelial cell 
co-cultures
Neither basal nor IFN-γ mediated secretion of IP-10 was
observed in A549/lymphocyte or Calu-3/lymphocyte co-
cultures (data not shown) Treatment with IL-12 did not
increase IP-10 levels in lymphocyte-Calu-3 co-cultures
and only modest IP-10 secretion was observed in lym-
phocyte/A549 co-cultures (0.006 ± 0.005 and 0.103 ±
0.209 ng/ml, respectively, n = 3).
Furthermore, low basal increase of IP-10 secretion was
observed in both Calu-3/monocyte and A549/monocyte
co-cultures (0.2 ± 0.1 and 0.3 ± 0.07 ng/ml, respectively,
n = 5) compared with Calu-3/PBMCs and A549/PBMCs
co-cultures (1.0 ± 0.3 and 3.0 ± 1.0 ng/ml, respectively, n
= 5), showing that the interactions between all three cell
types, monocytes, lung epithelial cells and lymphocytes,
are crucial for the basal secretion of IP-10. However, treat-
ment with recombinant IFN-γ increases IP-10 secretion in
monocyte/lung epithelial cell co-cultures in the absence
of lymphocytes (Calu-3/monocyte and A549/monocyte
co-cultures (2.6 ± 0.5 and 2.7 ± 0.7 ng/ml, respectively, n
= 5).
Inhibition of IP-10 secretion from PBMC/lung epithelial 
cell co-cultures
P38 inhibitor BIRB796, IKK-2 inhibitor V, beclometha-
sone, PDE4 inhibitor rolipram and PI3 kinase inhibitor
strongly and significantly inhibited basal IP-10 secretion
from PBMC and lung epithelial cell co-cultures (Table 2
and Figure 6.).
The IFN-γ (10 ng/ml) mediated IP-10 secretion in both
A549/PBMC co-cultures and Calu-3/PBMC co-cultures
was dose dependently inhibited by the PI3 kinase inhibi-
tor (Figure 6). In contrast, IL-12 mediated secretion of IP-
10 in Calu-3/PBMC co-cultures was significantly inhib-
ited by BIRB796, beclomethasone and rolipram (see Table
2). However there is a clear difference with the A549/
PBMC co-culture, whereby IL-12 mediated IP-10 secretion
was partially inhibited by beclomethasone and PI3 kinase
inhibitor only (see Table 2). Human CD40 antibody (10
µg/ml) did not have any effects on IP-10 secretion in co-
cultures (Table 2).
Inhibition of IFN-γ secretion from PBMC/A549 co-cultures
IL-12 mediated IFN-γ secretion in PBMC/A549 co-cultures
was inhibited significantly by p38 inhibitor BIRB796,
beclomethasone, and PI3 kinase inhibitor as seen in Table
3 and Figure 6.
IP-10 secretion in PBMC/NHBE co-cultures
As shown in Figure 7. no basal IP-10 secretion was
observed in PBMC/NHBE co-cultures. IFN-γ treatment sig-
nificantly increased IP-10 secretion from NHBEs and
PBMCs cultured alone. Interestingly, IFN-γ mediated IP-
10 secretion was significantly increased in co-cultures
compared to the PBMCs and NHBEs cultured alone in
agreement with the A549/PBMC and Calu-3/PBMC co-
cultures (See Figure 7).
Discussion
IP-10 was initially identified as IFN-γ inducible protein
[26], which was shown to be a potent chemokine for Th1
cells. Its receptor CXCR3 is predominantly expressed by
Th1 cells [18] but expression has also been shown in
many other cell types including lung epithelial cells [5].
Increased levels of both IP-10 and CXCR3 have been
shown in patients with COPD, and subsequently this
chemokine has been suggested to be involved in the
inflammatory process underlying COPD [23].
Basal, IFN-γ and IL-12 mediated secretion of IP-10 in lung  epithelial cell/PBMC co-cultures cultured in transwell cham- bers with separating filters Figure 5
Basal, IFN-γ and IL-12 mediated secretion of IP-10 in lung 
epithelial cell/PBMC co-cultures cultured in transwell cham-
bers with separating filters. Data represent the mean ± SEM 
of 4 independent experiments. Control () values are shown 
as IP-10 secretion in lung epithelial cell/PBMC co-cultures 
cultured in transwell chambers without a separating filter.
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The aim of the present studies was to examine the effects
of lung epithelial cells/PBMCs interaction on IP-10 secre-
tion. We used PBMCs from both non-smoking and smok-
ing volunteers since COPD is a smoking related disease.
However, no differences were found in IP-10 secretion
from PBMCs between non-smokers and smokers (results
not shown). This is likely due to the fact that all volunteers
used in the present study are healthy. However, at the
present studies we characterize the complex interaction
between PBMCs and lung epithelial cells on the regula-
Table 2: Inhibition of IP-10 secretion in co-cultures. The effects of 100 nM p38 inhibitor BIRB-796, 100 nM beclomethasone, 500 nM 
IKK-2 inhibitor V, 100 nM PDE4 inhibitor rolipram, 1 µM PI3 kinase inhibitor and human 10 µg/ml CD40 antibody on secretion of IP-10 
from co-cultures.
Calu-3/PBMC A549/PBMC
Basal IFN-γ IL-12 Basal IFN-γ IL-12
BIRB-796 84 (± 7) ** 18 (± 6) 85 (± 6) ** 94 (± 2) *** 14 (± 6) 21 (± 8)
IKK-2 inh. V 75 (± 11) * 3 (± 1) 60 (± 13) 90 (± 5) * 4 (± 6) 17 (± 5)
Beclomet. 97 (± 1) *** -7 (± 6) 94 (± 2) *** 89 (± 8) ** 1 (± 4) 43 (± 14) *
Rolipram 62 (± 13) * 8 (± 2) 82 (± 10) * 77 (± 11) ** 17 (± 15) 0.6 (± 4)
PI3 kin. Inh. 91 (± 5) *** 54 (± 9) 96 (± 3) ** 96 (± 3) *** 50 (± 7) 77 (± 8)
CD40 ab -14 (± 14) -2 (± 7) -5 (± 25) 19 (± 10) -9 (± 12) -12 (± 10)
Data represents the percentage of inhibition, mean (SEM). ***p < 0.001, **p < 0.01, *p < 0.05, ANOVA with Bonferroni's multiple comparison test.
The dose dependent inhibition of IP-10 secretion by PI3 kinase inhibitor in Calu-3/PBMCs (A.) and A549/PBMCs (B.) co-cul- tures with or without IFN-γ and IL-12 treatment Figure 6
The dose dependent inhibition of IP-10 secretion by PI3 kinase inhibitor in Calu-3/PBMCs (A.) and A549/PBMCs (B.) co-cul-
tures with or without IFN-γ and IL-12 treatment. The dose dependent inhibition by PI3 kinase inhibitor of IL-12 mediated IFN-
γ secretion in A549/PBMCs co-cultures is seen in (C.) Data represent the mean ± SEM of 4–7 independent experiments, *p < 
0.05, **p < 0.01, ***p < 0.001, ANOVA with Bonferroni's multiple comparison test.
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tion of IP-10 secretion by IFN-γ/IL-12 pathways. No basal
secretion of IP-10 was observed in either cell type cultured
alone, however, a significant increase of basal IP-10 secre-
tion was observed in PBMC/lung epithelial cell co-cul-
tures. The IP-10 secretion was found to be due to a specific
interaction between monocytes and lung epithelial cells
via cell-cell contact (Figure 8a), since no basal IP-10 secre-
tion was detected in PBMC/lung epithelial cell transwell
co-cultures. Surprisingly, no IP-10 secretion was observed
in monocyte/lung epithelial cell co-cultures in the
absence of lymphocytes. Since addition of recombinant
IFN-γ could restore the elevated IP-10 secretion in mono-
cyte/lung epithelial cell co-cultures, the significance of the
lymphocytes in co-cultures is most likely to the source of
endogenous IFN-γ (Figure 8b). A similar mechanism
might also be involved in EnC/PBMC co-cultures studied
by Raju et al. (2003) demonstrating that the basal secre-
tion of IP-10 from EnC/PBMC co-cultures is IFN-γ
dependent [9]. Therefore, it is likely that the increased
amounts of leucocytes in lung tissue in COPD patients
interact with several cell types including lung epithelial
cells as well as endothelial cells in a similar manner
increasing IP-10 secretion.
However, there are crucial differences in the IP-10 secre-
tion from different types of co-cultured cells. In our study
CD40 is not involved in the cell-cell interaction depend-
ent basal IP-10 secretion, whereas CD40 has been
reported to mediate IP-10 secretion in EnC/monocyte co-
cultures [7]. Moreover, antibodies against ICAM, CD11b
and CD18b have been used to show the importance of
these proteins in leucocyte/synoviocyte IP-10 induction
[10].
IP-10 is classically induced by IFN-γ, however, in the
present studies no detectable basal secretion of IFN-γ was
In summary, basal IP-10 secretion is induced by monocyte- epithelial cell interactions, with a presence of lymphocytes,  most likely to provide a source of IFN-γ Figure 8
In summary, basal IP-10 secretion is induced by monocyte-
epithelial cell interactions, with a presence of lymphocytes, 
most likely to provide a source of IFN-γ. The interaction of 
monocytes and lung epithelial cells are made by direct cell-
cell contact. (A). Addition of recombinant IFN-γ induces 
strong IP-10 secretion in co-cultures even in absence of lym-
phocytes. Moreover, a secreted factor from lung epithelial 
cells augments the IFN-γ mediated secretion of IP-10 from 
monocytes (B). Addition of recombinant IL-12 induces IFN-γ 
independent IP-10 secretion in Calu-3/PBMC co-cultures 
which cannot be blocked by IFN-γ antibodies. Moreover, no 
detectable IFN-γ is present and Calu-3 cells secrete a factor 
which augments IP-10 secretion from monocytes in response 
to IL-12 (C). Addition of recombinant IL-12 induces IP-10 
secretion both by inducing IFN-γ secretion from lymphocytes 
and by an IFN-γ independent pathway, which cannot be 
blocked by IFN-γ antibodies (D).
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Table 3: Inhibition of IFN-γ secretion in co-cultures. The effects 
of 100 nM p38 inhibitor BIRB-796, 100 nM beclomethasone, 500 
nM IKK-2 inhibitor V, 100 nM PDE4 inhibitor rolipram, 1 µM PI3 
kinase inhibitor and human 10 µg/ml CD40 antibody on secretion 
of IP-10 from co-cultures.
A549/PBMC + IL-12
BIRB-796 99 (± 0) ***
IKK-2 inh. V 11 (± 9)
Beclomet 98 (± 0) ***
Rolipram 26 (± 7)
PI3 kin. Inh. 77 (± 7)*
CD40 ab 26 (± 11)
Data represents the percentage of inhibition, mean (SEM). ***p < 
0.001 and *p < 0.05, ANOVA with Bonferroni's multiple comparison 
test.
Basal and IFN-γ mediated secretion of IP-10 in NHBE/PBMC  co-cultures Figure 7
Basal and IFN-γ mediated secretion of IP-10 in NHBE/PBMC 
co-cultures. Data represent the mean ± SEM of 4 independ-
ent experiments, ***p < 0.001, *p < 0.05 with ANOVA.
- 1 10 - 1 10 - 1 10
0
1
2
3
4
5
6
7
8
IFN-g ng/ml
PBMC                   NHBE           PBMC+NHBE
*
***
***
***
***
I
P
-
1
0
 
n
g
/
m
lRespiratory Research 2007, 8:80 http://respiratory-research.com/content/8/1/80
Page 9 of 11
(page number not for citation purposes)
observed in the co-cultures. Nevertheless, antibodies
against IFN-γ blocked the IP-10 secretion from co-cul-
tures, suggesting that low levels of endogenous IFN-γ,
undetectable with ELISA, are present in co-cultures The
detection range for the IFN-γ ELISA is from ~0.015–1 ng/
ml. The lowest detectable concentration would not be
able to stimulate IP-10 secretion in PBMC cultures, since
we did not detect any IP-10 secretion with 0.1 ng/ml IFN-
γ (Figure 1). However, as shown in Figure 1, addition of
0.1 ng/ml IFN-γ strongly augments basal IP-10 secretion
in Calu-3/PBMC co-cultures, which did not secrete any
detectable levels of endogenous IFN-γ, suggesting that
even a very low concentration of endogenous IFN-γ can
induce strong IP-10 secretion when there are direct cellu-
lar interactions between monocyte and lung epithelial
cells. The increasing concentrations (0.1–10 ng/ml) of
IFN-γ resulted in a dose dependent increase in IP-10 secre-
tion in co-cultures (Figure 1).
As previously described, IP-10 is specifically secreted by
the monocytes in PBMCs. Interestingly, monocytes cul-
tured in the conditioned media from either epithelial cell
line, together with recombinant IFN-γ, induce significant
increase in IP-10 secretion. These results suggest that a
secreted factor from epithelial cell lines is at least partially
responsible for the IFN-γ mediated IP-10 secretion in co-
cultures. A recent study by Boulday et al. (2006) reported
that vascular endothelial growth factor (VEGF) augments
the IFN-γ mediated secretion of IP-10 in endothelial cells
[27]. Interestingly, Koyama et al [28] show that A549 epi-
thelial cells constitutively express high levels of VEGF and
that this is augmented by IFN-γ. Whilst our studies con-
firm the high constitutive VEGF secretion (data not
shown) neither human recombinant VEGF nor VEGF
inhibitors had any effects on IP-10 secretion from mono-
cytes. These data suggest that there are distinct soluble fac-
tors governing the IP-10 response in endothelial versus
epithelial cells. The secreted factor from lung epithelial
cells might be a growth factor, interleukin or interferon,
since previous studies have shown an inducible expres-
sion of IP-10 in a wide variety of tissues and cells under
the influence of stimuli including interferons, inter-
leukins, lipopolysaccharide, tumor necrosis factor-α,
platelet derived growth factor, and hypoxia [6].
IL-12 is a classic IFN-γ inducing cytokine, which induced
secretion of endogenous IFN-γ in A549/PBMC co-cultures
due to a specific interaction between lymphocytes and
A549 cells IL-12 also induced an increase in IP-10 secre-
tion in A549/PBMC co-cultures, potentially partly due to
endogenous IFN-γ signalling. The IL-12 mediated induc-
tion of IFN-γ and IP-10 secretion in A549/PBMC co-cul-
tures is via intercellular contact as this was only observed
in co-cultures and not in transwells or conditioned media
studies. Interestingly, IFN-γ antibody pre-treatment only
partially inhibited IL-12 mediated IP-10 induction, sug-
gesting that there may be both IFN-γ dependent and inde-
pendent IP-10 induction pathways.
In contrast to A549/PBMC co-cultures, IL-12 significantly
increased IP-10 secretion in Calu-3/PBMC co-cultures in
the absence of any detectable increase in IFN-γ levels
(Compare Figures 8c and 8d). Moreover, the IL-12 medi-
ated IP-10 secretion was shown to be IFN-γ independent,
since it could not be inhibited by the IFN-γ ab in Calu-3/
PBMC co-cultures. This IL-12 mediated IP-10 secretion is
likely to be mediated at least in part via a secreted factor
from Calu-3 cells as it is maintained in conditioned media
and transwell studies.
To further probe the signalling pathways involved in
modulating IP-10 expression in the epithelial cell/PBMC
co-cultures, we investigated the pharmacological effect of
a number of signal transduction pathway inhibitors on
this model. Present studies suggest that there are at least
two pathways by which IP-10 can be induced which are
either IFN-γ dependent or IL-12 dependent.
IFN-γ dependent IP-10 expression was sensitive to PI3K
inhibitors and independent of signalling via IKK-2, p38 or
PDE4. Interestingly, whilst corticosterioids are frequently
prescribed for lung inflammation, they again did not
modulate IFN-γ induced IP-10 expression in this system.
As IFN-γ signals via a JAK-STAT1 pathway [2], resistance to
these inhibitors would be expected, but the role of PI3K is
very exciting. The PI3 kinase inhibitor PIK-93 used in the
present studies targets several PI3 kinases and has high
potency for the class I PI3 kinases p110α as well as p110γ.
[25] The development of subtype specific inhibitors will
help identify which subtype of PI3 kinase is responsible
for the increased IP-10 expression in co-cultures. Consist-
ent with these results, it has been reported that the non-
selective PI3K inhibitor wortmanin can also inhibit IFN-g
mediated IP-10 production from endothelial cells [27].
These studies suggest that the development of PI3K inhib-
itors may represent a novel anti-inflammatory treatment
for COPD, as they will inhibit a pathway not modulated
by current therapies.
In contrast, IL-12 mediated IP-10 induction was sensitive
to each of the inhibitors tested, except antibodies to IFN-
γ. This provides further evidence therefore, that there are
at least two pathways for IP-10 induction, with the latter
being dependent upon the classical inflammatory path-
ways, NFκB and p38 MAP kinase, as well as cAMP. More-
over, the IL-12 signalling cascade has previously been
shown to be sensitive to dexamethasone, [29] and the
present studies show that the IL-12 mediated induction of
IP-10 in co-cultures is modulated by corticosteroids,Respiratory Research 2007, 8:80 http://respiratory-research.com/content/8/1/80
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which may contribute to the efficacy of these agents in
treatment of respiratory inflammation.
The differences in IL-12 mediated IP-10 secretion between
Calu-3/PBMC and A549/PBMC co-cultures were also evi-
dent in the inhibitor studies. Inhibition of IP-10 secretion
in A549/PBMC co-cultures was only effectively inhibited
by PI3K inhibitors and partially inhibited by dexametha-
sone. As these co-cultures were shown to endogenously
express IFN-γ (Table 1), this would suggest that most of
the drive to induce IP-10 was due to the IFN-γ JAK-STAT1
pathway, in addition to some residual signalling via a ster-
oid sensitive pathway. In contrast, all inhibitors used in
the present study strongly inhibited IP-10 secretion in
Calu-3/PBMC co-cultures, suggesting IFN-γ signalling is
not required for induction of IP-10. These differences
might reflect the differences in bronchiolar vs alveolar
lung epithelial tissue, which would have to be taken into
account in design of novel inhibitors blocking the abnor-
mally high IP-10 secretion in lung tissue of COPD
patients.
In addition to the human lung epithelial cell lines, we also
used the primary human epithelial cultures for the key
experiments. In contrast to A549 and Calu-3, NHBEs cul-
tured alone secrete IP-10 if pretreated with IFN-γ. Consist-
ent with this result Sauty et al. reported that pre-treatment
with IFN-γ induces IP-10 secretion in NHBEs but not in
A549 cells [5]. However, in agreement with the results
from A549/PBMCs and Calu-3/PBMCs co-cultures, signif-
icantly increased IFN-γ mediated IP-10 secretion was
observed from NHBE/PBMC co-cultures compared with
NHBEs or PBMCs cultured alone. This demonstrates a sig-
nificant increase in IFN-γ mediated IP-10 secretion in
PBMCs co-cultured with all lung epithelial cell lines as
well as the primary bronchial epithelial cells used in the
present study. These results indicate that PBMC-lung epi-
thelial cell interactions are strongly promoting IP-10
secretion in response to IFN-γ, thereby attracting more
lymphocytes to lung tissue and support the use of the
A549 and CALU-3 cell lines as a model of the primary cell
system. As example, application of cigarette smoke extract
in the leucocyte-lung epithelial cell co-cultures or to the
conditioned media is likely to provide an interesting addi-
tional in vitro model for COPD.
Since IP-10 is a potent chemoattractant for T cells, the sup-
pression of the increased IP-10 levels in lung tissue of
COPD patients may reduce the lung inflammation charac-
teristic of this disease. Increasing IP-10 levels will cause a
positive feedback loop attracting more T cells to the
peripheral airways, in turn increasing IFN-γ secretion.
Establishing a method to inhibit this positive feedback
loop may be profitable in suppressing the inflammatory
process underlying COPD. Barnes et al. (2004) suggests
that T cell inhibitory strategies, such as the use of immu-
nosuppressant's, might be effective in COPD, although
side effects, such as increasing the risk of bacterial infec-
tion, is of particular concern. Inhibition of IFN-γ signaling
may provide another approach [1]. As shown in the
present study, basal IP-10 secretion in co-cultures is
blocked with all inhibitors used, representing both cur-
rent and experimental therapies for respiratory disease.
However, in the presence of IFN-γ which is secreted by T
cells in peripheral airways IP-10 secretion is only inhib-
ited by inhibitors of PI3K. This in vitro model may repre-
sent the environment in the peripheral airways of COPD
patients which contain a large number of Th1 T cells, and
suggest that IP-10 mediated inflammation is not being
addressed with current respiratory therapies such as corti-
costeroids in these patients. However, this pathway was
modulated by non-isozyme selective PI3K inhibitors in
this model. A number of Pharmaceutical companies are
developing PI3K inhibitors and these results complement
an emerging body of data that suggest they may also have
utility in treating the inflammation associated with COPD
[30].
Conclusion
IP-10 secretion is a potent chemokine for CD8 T cells and
its expression is induced when circulating monocytes, T
cells and epithelium are in close proximity. Moreover,
expression of this chemokine is induced by signaling mol-
ecules such as IFN-γ and IL-12 known to be expressed in
COPD. Therefore, it is tempting to speculate that thera-
pies targeted at decreasing the levels of IP-10 in peripheral
airways of COPD patients may have therapeutic benefit in
the management of this disease. In the present studies we
demonstrate a complex interaction between monocytes,
lymphocytes and lung epithelial cells resulting in IP-10
secretion via multiple pathways. Furthermore, inhibition
studies supported the suggestion that different intracellu-
lar pathways are responsible for IFN-γ and IL-12 mediated
IP-10 secretion. These results may provide novel strategies
for investigating means by which to modulate IP-10 medi-
ated secretion and chemotactic effects on T cells.
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